Clinical Research Industry Report

CONTENTS Overview

Page 03 Page 04 Page 05 Page 06 Page 07

Clinical Research Organisations Pharmaceuticals Top Firms About Cpl Life Sciences | Vacancysoft

Overview For the pharmaceuticals sector, one by-product of COVID-19 is that regulators prioritized approving trials related to the virus and the focus was there. As a result, it is not a surprise that within the MHRA, a backlog developed, where the delay in trials being approved has had implications for the industry. As a result, it is fair to say that 2023 has seen significantly lower levels of recruitment for clinical-specific functions when compared to prior years. That has been compounded by quantitative tightening, meaning that funding for new R&D, resulting in additional phase one trials has also stalled.

03

Annual Totals

All Clinical Vacancies, Life Sciences, 2021-2023* Est, Europe

15,000

10,000

5,000

With that we see the following:

• Clinical vacancies in 2023 are set to be 34.9% lower than in 2022. • This reduction is broadly in line with industry trends, which have also seen a significant drop (-33.3%.) • Q3 2023 has had recruitment for clinical positions drop to levels not seen in the last five years, when analyzed by business quarter. • The proportion of clinical vacancies across Life Sciences which are within the CRO’s specifically has fallen from 64% in 2021 to 60% this year to date. It is perhaps for this reason the Government has stepped into action. The MHRA has been resourced to address the backlog, where since July, nearly 2000 trials have been approved when in a normal given 12-month period, the approval number would range between 500- 750. Hence looking ahead, as trials are approved, our forecast is bullish. Put it another way, if in 2023 clinical vacancies were 50% lower than in 2019, the last business year pre-pandemic, just for the recruitment to return to the levels seen then, would mean a doubling of vacancies in 2024. And that’s before we consider the implications of four times more trials being approved this year than in a regular one. Expect, therefore, 2024 to be busy.

2021

2022

2023*

Fig. 01 Source: Vacancysoft Analytics

*- Forecast 2023

All Clinical Vacancies, Life Sciences, 2021-2023* Est, Europe Annual % Breakdown

80%

127,511

60%

40%

20%

CRO

Pharmaceuticals

Biotechnology

2023*

2021

2022

Source: Vacancysoft Analytics

Fig. 02

*- Forecast 2023

Made with FlippingBook - professional solution for displaying marketing and sales documents online